This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Palau Pharma, S.A.
Drug Names(s): UR-65318
Description: UR-65318 is a histamine H4 receptor (H4R) intended to provide relevant anti-inflammatory activity and an early control of atopic dermatitis symptoms.
H4R is a G-protein coupled receptor that is widely distributed in skin and is over expressed in atopic dermatitis patients. Data from several preclinical in vitro and in vivo studies suggest that this novel target plays a key role in allergic and immuno-inflammatory disorders. Furthermore, the H4R regulates chemotaxis of inflammatory cells and has been proven to be highly involved in the mechanism of pruritus.
In June 2012, Palau signed an asset purchase agreement whereby the company has sold UR-65318 to a leading U.S., NYSE-listed pharmaceutical company. Financial terms of the agreement have not been disclosed. Under the agreement, Palau receives an initial cash payment and will receive additional future payments based on milestones to be reached during the development and commercialization stages.
Additional information available to subscribers only: